{"title":"骨修饰剂治疗肺癌骨转移的比较疗效:免疫治疗时代。","authors":"Dongmei Sun, Hui Zhu, Qinhao Xu, Yujie Wang, Yuezheng Peng, Yaru Tian, Jinming Yu, Zhe Wang","doi":"10.1080/14796694.2025.2525744","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Denosumab and bisphosphonates are commonly used in clinical practice for lung cancer patients with bone metastasis to prevent skeletal-related events (SREs). The aim of this study was to evaluate the efficacy of these two bone-modifying agents(BMAs)in advanced lung cancer patients with bone metastasis in the era of immunotherapy.</p><p><strong>Methods: </strong>Electronic medical records of advanced lung cancer patients with bone metastasis between January 2020 and March 2023 were retrospectively reviewed. Overall survival (OS), progression-free survival (PFS), and the time to the first occurrence of SRE were calculated using the Kaplan - Meier method and were compared using the log-rank test.</p><p><strong>Results: </strong>Among the 227 included patients, denosumab significantly improved OS by 5.41 months compared with bisphosphonates (27.54 months <i>vs</i>. 22.13 months; hazard ratio (HR): 0.61; <i>p</i> = 0.031). Denosumab also delayed the time to the first occurrence of SRE (undefined <i>vs</i>. 31.64 months; HR: 0.43, <i>p</i> = 0.005) and reduced the incidence of multiple SREs. However, the incidence of hypocalcemia at grade ≥ 3 was higher in the denosumab group than in the bisphosphonate group (8.6% <i>vs</i>. 3.0%).</p><p><strong>Conclusions: </strong>In patients with bone metastatic lung cancer, the efficacy of denosumab was significantly higher than that of bisphosphonate.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2483-2493"},"PeriodicalIF":2.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330236/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comparative efficacy of bone-modifying agents in the treatment of lung cancer bone metastases: immunotherapy era.\",\"authors\":\"Dongmei Sun, Hui Zhu, Qinhao Xu, Yujie Wang, Yuezheng Peng, Yaru Tian, Jinming Yu, Zhe Wang\",\"doi\":\"10.1080/14796694.2025.2525744\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>Denosumab and bisphosphonates are commonly used in clinical practice for lung cancer patients with bone metastasis to prevent skeletal-related events (SREs). The aim of this study was to evaluate the efficacy of these two bone-modifying agents(BMAs)in advanced lung cancer patients with bone metastasis in the era of immunotherapy.</p><p><strong>Methods: </strong>Electronic medical records of advanced lung cancer patients with bone metastasis between January 2020 and March 2023 were retrospectively reviewed. Overall survival (OS), progression-free survival (PFS), and the time to the first occurrence of SRE were calculated using the Kaplan - Meier method and were compared using the log-rank test.</p><p><strong>Results: </strong>Among the 227 included patients, denosumab significantly improved OS by 5.41 months compared with bisphosphonates (27.54 months <i>vs</i>. 22.13 months; hazard ratio (HR): 0.61; <i>p</i> = 0.031). Denosumab also delayed the time to the first occurrence of SRE (undefined <i>vs</i>. 31.64 months; HR: 0.43, <i>p</i> = 0.005) and reduced the incidence of multiple SREs. However, the incidence of hypocalcemia at grade ≥ 3 was higher in the denosumab group than in the bisphosphonate group (8.6% <i>vs</i>. 3.0%).</p><p><strong>Conclusions: </strong>In patients with bone metastatic lung cancer, the efficacy of denosumab was significantly higher than that of bisphosphonate.</p>\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"2483-2493\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330236/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2025.2525744\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2525744","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Comparative efficacy of bone-modifying agents in the treatment of lung cancer bone metastases: immunotherapy era.
Aim: Denosumab and bisphosphonates are commonly used in clinical practice for lung cancer patients with bone metastasis to prevent skeletal-related events (SREs). The aim of this study was to evaluate the efficacy of these two bone-modifying agents(BMAs)in advanced lung cancer patients with bone metastasis in the era of immunotherapy.
Methods: Electronic medical records of advanced lung cancer patients with bone metastasis between January 2020 and March 2023 were retrospectively reviewed. Overall survival (OS), progression-free survival (PFS), and the time to the first occurrence of SRE were calculated using the Kaplan - Meier method and were compared using the log-rank test.
Results: Among the 227 included patients, denosumab significantly improved OS by 5.41 months compared with bisphosphonates (27.54 months vs. 22.13 months; hazard ratio (HR): 0.61; p = 0.031). Denosumab also delayed the time to the first occurrence of SRE (undefined vs. 31.64 months; HR: 0.43, p = 0.005) and reduced the incidence of multiple SREs. However, the incidence of hypocalcemia at grade ≥ 3 was higher in the denosumab group than in the bisphosphonate group (8.6% vs. 3.0%).
Conclusions: In patients with bone metastatic lung cancer, the efficacy of denosumab was significantly higher than that of bisphosphonate.
期刊介绍:
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.